Biotech Startups

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.

6 investors

Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases. The company combines RNA biology expertise with machine learning to advance precision medicines.

6 investors

Equator Therapeutics develops first-in-class drugs targeting mitochondrial thermogenesis to treat obesity and metabolic disorders by restoring the body's natural heat production mechanism. The company uses bioelectricity research and high-throughput assays to identify selective activators of thermogenic compounds in mitochondria.

6 investors

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

6 investors

Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.

6 investors

Excepgen is a biotech company based in San Francisco.

6 investors

FA Bio (formerly FungiAlert) discovers unique soil microbes to develop microbial-based biocontrol and biostimulant products for growers, aiming to replace agrochemicals and reduce farming's environmental impact. The company, spun out of Imperial College London, uses its SporSenZ technology for soil microbial analysis in the agri-tech sector.

6 investors

FabricNano develops cell-free biocatalysis technology that immobilizes engineered enzymes onto scalable, environmentally friendly support materials for use in bio-processes. It offers enzyme immobilization and interaction engineering services to help companies turn biocatalysis projects into commercially viable, scalable biocatalyst products.

6 investors

Ferronova develops magnetic iron-oxide nanoparticle tracers (FerroTrace) and related imaging and therapy technologies to detect and map lymph nodes and tumours in early-stage cancers, supporting surgeons, oncologists and pathologists in staging and treating cancers such as oral, colorectal, esophageal, prostate and pancreatic. Spun out from the University of South Australia and Victoria University, the company is based in Australia.

6 investors

Fluid Biomed develops a bioresorbable polymer-based stent designed to treat brain aneurysms by diverting blood flow and reducing risk of stroke. The company targets patients with cerebrovascular conditions and is advancing the technology toward regulatory approval and commercial deployment.

6 investors

Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.

6 investors

Fork & Good develops cultivated meat technology using a hydroponic system approach that integrates cell biology with farming principles to produce real meat from cells at scale. The company serves food manufacturers and works toward making cultivated meat commercially viable and sustainable.

6 investors

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases. It serves patients, healthcare providers, and biopharma companies, with tests available across all U.S. states and 45+ countries.

6 investors

Frontier Bio develops tissue engineering and bioprinting technology, including fabrication of tissue-engineered blood vessels for clinical and in vitro applications. The company works at the intersection of biology and engineering in the biotech and medical device space.

6 investors

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome. It uses a platform that maps druggable sites to generate a pipeline of novel therapeutic leads.

6 investors

General Biological converts agricultural feedstock into high-value industrial chemicals at a bio-based manufacturing facility on the Mississippi River in Northeast Louisiana. It aims to rebuild a domestic U.S. chemical supply chain for critical industrial molecules using stranded agricultural infrastructure.

6 investors

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.

6 investors

Granata Bio is a US-based biopharmaceutical company focused on reproductive health and fertility, in-licensing IVF medications used outside the US to develop and commercialize them in North America. Its aim is to expand therapeutic options, lower costs, and increase access to fertility treatment for patients.

6 investors

Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.

6 investors

Holoclara develops therapeutics derived from symbiotic intestinal organisms (helminths) that modulate inflammation, metabolism, and tissue regeneration to address chronic disease, immune-related conditions, and aging. The company aims to reintroduce beneficial worm-derived components without live worms.

6 investors

Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.

6 investors

Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

6 investors

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases. The company focuses on advancing treatments in cancer immunotherapy and inflammation-related conditions.

6 investors

Impetus Ag develops early- to late-stage agricultural technologies, with a focus on Bt discovery and development and insecticidal proteins for insect and pest control in crops. It operates in the agricultural biotech sector, building plant trait and biological R&D solutions.

6 investors